摘要
目的:研究精神分裂症患者MDR1C3435T基因多态性与帕利哌酮缓释片疗效的相关性。方法:收集服用非典型抗精神病药物帕利哌酮缓释片患者68例,采用阳性和阴性症状量表(PANSS)评定疗效,个人与社会功能量表(PSP)评定社会功能,根据PANSS减分率(≥50%为有效)分为有效组和无效组。采用聚合酶链反应-限制性片段长度多态性分析(PCR-RFLP)技术检测其MDR1C3435T位点的基因型。将有效组和无效组的基因型进行卡方检验。结果:治疗前后PANSS及PSP量表评分比较差异有统计学意义(P<0.001),有效组与无效组基因型差异无统计学差别(P>0.05)结论:帕利哌酮缓释片治疗精神分裂症疗效肯定,未发现MDR1C3435T基因多态性与帕利哌酮的疗效有关。
Objective：To investigate the genotypes of C3435T of MDR1 gene in peripheral blood of patients with schizophrenia, and analyze the association between C3435T genetic polymorphism of MDR1 gene with efficacy of pailperidone extended-release tablets. Method： 68 schizophrenia patients who took pailperidone extended-release tablets were included in the study. They were assessed with positive and negative symptoms scales （PANSS） and the personal and social performance scale （PSP）. The patients were divided into responsive group and unresponsive group by the score of PANSS reduction rate. C3435T polymorphism was analyzed by the polymerase chain reaction restriction fragment length polymorphism （PCR-RFLP） method. The results were analyzed by Chi-square test. Results：There was marked difference between the score of PANSS and PSP before and after 6 weeks treatment for Pailperidone extended-release tablets. The differences of genotype in the responsive group and unresponsive group were not significant （P 〉 0.05）. Conclusion： Pailperidone extendedrelease tablet was found to be effective in improving psychotic and personal and social performance. The relationship was not found between C3435T genetic polymorphism of MDR1 gene and the efficacy of paliperidone ER in patients with schizophrenia.
出处
《临床精神医学杂志》
2012年第1期5-8,共4页
Journal of Clinical Psychiatry
基金
广东省自然科学基金资助项目(8151018004000001)(9151503102000013)
